Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
about
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityrPhase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphomaThe use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation.Current management of follicular lymphomas.Current treatment options in follicular lymphoma: science and bias.Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma.Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.Radioimmunotherapy in mantle cell lymphoma.Radioimmunotherapy for B-cell non-hodgkin lymphomas.Radionuclide therapy beyond radioiodine.Novel antibody-based proteins for cancer immunotherapy.Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.Title: Rituximab: A Benchmark in the Development of Chemotherapy-free Treatment Strategies for Follicular Lymphomas.Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab.Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
P2860
Q24633710-63A9A90F-9170-48F7-B73D-64D9D8B82791Q26776480-689A0164-A82E-40D0-8243-E6293B25276EQ33374978-0C20543C-CFC6-4712-AF3B-7BC00B8AB63AQ33645793-58F1815F-71E0-4447-BE1F-165F78E57D5AQ34585773-6F0A9CA4-53B4-4032-9F15-F7F8DBF41F81Q35786490-7459AAE3-249F-451B-800A-3B0FD80445DAQ35867299-F4083736-65DB-4989-A1D7-D4F5753AAF14Q36639053-DBF3EE09-3263-446D-8977-42A63BB36C18Q36966780-C1EA3665-2C90-44B9-9B71-C24677CBFE88Q36979699-81472229-6E98-41D9-B1A0-2D67AAF8DB26Q37169112-A9823772-D28A-406B-8665-A815EDAC1231Q37174938-FA2C73D6-EFAE-44AD-AC07-3DED96BF7FE1Q37752447-3DCFEE3D-9890-42C7-8258-AF9FCE1C572EQ37824258-1BEE08EC-B259-43C5-9B2A-008E02FBFE63Q37877728-A074BF1E-89C9-46DF-8F63-1612ECC4F061Q38017790-52337C7D-17B7-45A9-B0C1-8F66E0A1B4B5Q38019790-3CD35B71-14FA-4F09-862F-76CA4E2A27BAQ38027798-7B897F2A-8A64-416F-B448-DDBDDEA0DC8EQ38161370-FA855048-5BE9-4D99-A4FB-AABC2E1CBF3DQ38396244-6F62E30D-9808-44B7-B3F3-1DA3F9542579Q38473731-DCA191AA-5854-459E-A012-6FE52D3F788DQ47365893-D42FC404-00BD-425E-BB33-50CD4C3FEB30Q52689720-D7152B70-3932-4334-AC22-71C9F478B3D6Q52951948-1C70C94D-1BCF-4F3E-8BCA-3802501EF7D6Q53201392-79590E33-8798-4C56-9934-9F2F5BF0B907
P2860
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@ast
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@en
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@nl
type
label
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@ast
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@en
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@nl
prefLabel
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@ast
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@en
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@nl
P2093
P2860
P1433
P1476
Treatment with yttrium 90 ibri ...... B-cell non-Hodgkin's lymphoma.
@en
P2093
Arturo Molina
Christos Emmanouilides
Gregory A Wiseman
Ian W Flinn
Leo I Gordon
Mohamed Darif
Russell J Schilder
Thomas E Witzig
P2860
P304
P356
10.1080/10428190500376076
P577
2006-04-01T00:00:00Z